Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for auto industry professionals · Monday, July 23, 2018 · 456,373,034 Articles · 3+ Million Readers

Clinigen and Mitsubishi Tanabe Initiate European Managed Access Program for Edaravone to Treat ALS

Clinigen logo

Burton-On-Trent, England, May 22, 2018 / B3C newswire / -- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).

Edaravone is approved for use as a treatment for ALS in Japan, South Korea and the USA.

ALS is an idiopathic neurodegenerative disease in which motor neurons selectively degenerate and vanish. Muscle strength declines throughout the entire body, including the limb, facial, and respiratory muscles, and muscular atrophy progress. The cause for the majority of cases is not well understood, but may involve genetic and environmental factors. It is one of the best known neuromuscular diseases and affects approximately two in 100,000 people worldwide.

John Lagus, Head of Managed Access, Clinigen, said:

“We are pleased to once again be working with MTPC to help eligible patients in Europe gain access to this important medicine.

“As the trusted global leader in access to unlicensed medicines, this partnership aligns with our mission of getting the right medicines to the right patient at the right time.”

Healthcare professionals can obtain details about the edaravone Managed Access Program by calling the medicine access team at +44 1283 494 340, or emailing medicineaccess@clinigengroup.com. Access to more information can also be obtained through Cliniport at https://cliniport.co.uk/.

Contacts

Clinigen Group plc Shaun Chilton, Group Chief Executive Officer John Lagus, Head of Managed Access +44 (0) 1283 495010

Instinctif Partners Melanie Toyne-Sewell / Alex Shaw / Deborah Bell +44 (0) 20 7457 2020 clinigen@instinctif.com

Powered by EIN Presswire
Distribution channels: Technology
Submit your press release